ArticleFrontiers in medicine2023
Classification system for nanotechnology-enabled health products with both scientific and regulatory application.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Bridging functional bionanomaterials and the clinic: strategic communication as a translational enabler.Journal of nanobiotechnology · 2026Review
- Integration of nanotechnology in triple negative breast cancer research: a bibliometric and emerging trends analysis.Discover nano · 2026Review
- Nanomaterials as electrochemical regulators of bacterial biofilms through the modulation of extracellular electron transport and ion channels.Journal of nanobiotechnology · 2026Review
- Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.International journal of nanomedicine · 2026Review
- Enzyme Immobilization on Nanomaterials and Their Applications.Materials (Basel, Switzerland) · 2025Review
- Development of Glycyrrhizic Acid Nanoparticles for Modulating Gastric Ulcer Healing: A Comparative In Vivo Study Targeting Oxidative Stress and Inflammatory Pathways.Antioxidants (Basel, Switzerland) · 2025Article
- Micro- and Nanoengineered Devices for Rapid Chemotaxonomic Profiling of Medicinal Plants.Nanomaterials (Basel, Switzerland) · 2025Review
- Implementing Horizon Scanning as a tool for the strategic development of regulatory guidelines for nanotechnology-enabled health products.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of specific regulatory guidelines for nanotechnology-enabled health products (NHPs) is hampering development and patient access to these innovative technologies. Namely, there is an urgent need for harmonized regulatory definitions and classification systems that allow establishing a standardized framework for NHPs regulatory assessment. In this work, a novel classification system for NHPs is proposed. This classification can be applied for sorting nano-based innovations and regulatory guidelines according to the type of NHPs they address. Said methodology combines scientific and regulatory principles and it is based on the following criteria: principal mode of action, chemical composition, medical purpose and nanomanufacturing approach. This classification system could serve as a useful tool to sensor the state of the art of NHPs which is particularly useful for regulators to support strategy development of regulatory guidelines. Additionally, this tool would also allow manufacturers of NHPs to align their development plans with their applicable guidelines and standards and thus fulfill regulators expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.